-$0.52 Earnings Per Share Expected for Ra Pharmaceuticals Inc (RARX) This Quarter

Wall Street brokerages forecast that Ra Pharmaceuticals Inc (NASDAQ:RARX) will announce earnings of ($0.52) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.51). Ra Pharmaceuticals posted earnings per share of ($0.68) in the same quarter last year, which indicates a positive year-over-year growth rate of 23.5%. The business is expected to issue its next earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Ra Pharmaceuticals will report full year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($2.22) to ($2.07). For the next financial year, analysts expect that the company will report earnings of ($2.11) per share, with EPS estimates ranging from ($2.28) to ($1.95). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Ra Pharmaceuticals.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01.

A number of equities research analysts have recently commented on RARX shares. BidaskClub cut shares of Ra Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 5th. ValuEngine raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday, August 14th. Raymond James started coverage on shares of Ra Pharmaceuticals in a report on Thursday, June 28th. They issued an “outperform” rating and a $18.00 target price for the company. Finally, Credit Suisse Group upped their target price on shares of Ra Pharmaceuticals from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, August 7th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $19.00.

Large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its holdings in shares of Ra Pharmaceuticals by 817.8% in the first quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock valued at $106,000 after buying an additional 17,820 shares during the last quarter. Gabelli Funds LLC acquired a new position in shares of Ra Pharmaceuticals during the second quarter worth about $120,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Ra Pharmaceuticals during the first quarter worth about $128,000. Nisa Investment Advisors LLC acquired a new position in shares of Ra Pharmaceuticals during the second quarter worth about $157,000. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Ra Pharmaceuticals by 50.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 32,800 shares of the company’s stock worth $175,000 after acquiring an additional 11,000 shares during the period. 72.30% of the stock is owned by institutional investors and hedge funds.

Shares of RARX opened at $16.42 on Friday. Ra Pharmaceuticals has a 1-year low of $4.78 and a 1-year high of $19.43. The firm has a market capitalization of $585.03 million, a P/E ratio of -6.81 and a beta of 1.42.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Do Tariffs Work?

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply